Can I Legally Use Psilocybin for Depression, Trauma, or End-of-Life Distress?

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Adults who are experiencing depression, PTSD, trauma, or end-of-life distress and want to understand what legal options currently exist in the United States for accessing psilocybin.

The short answer

Three states have created legal pathways for adults to access psilocybin: Oregon, Colorado, and New Mexico. Oregon and Colorado programs are operating now. New Mexico’s program is still being built and is not yet enrolling patients. Outside these three states, the only legal pathways are clinical trials — federally authorized research studies with their own eligibility requirements and limitations. Psilocybin remains a Schedule I controlled substance under federal law regardless of what state you are in.

What the law allows right now

Oregon

Oregon’s psilocybin services program has been operating since summer 2023 under the Oregon Psilocybin Services Act (Ballot Measure 109, approved November 2020). Adults 21 and older — including non-Oregon residents — can access supervised psilocybin sessions at a licensed service center, administered by a licensed facilitator.

Oregon does not require a diagnosis, a referral, a prescription, or a clinical indication. Someone experiencing depression, trauma, or end-of-life distress can access the program on the same terms as anyone else. The session structure includes a preparation session, a supervised administration session at the service center, and an optional integration session within 72 hours. All sessions are out of pocket — insurance does not cover Oregon psilocybin services — with costs typically ranging from $1,000 to $3,000 or more depending on the provider. Roughly 360 licensed facilitators and approximately 30 operating service centers were active as of late 2025, though the number has been shifting as some early centers have closed and others have opened.

The Oregon program provides access to supervised experiences, not medical treatment. Licensed facilitators are not therapists. They do not diagnose conditions, prescribe substances, or provide psychotherapy.

Colorado

Colorado’s Natural Medicine Health Act (Proposition 122, approved November 2022) created a licensed healing center program administered by the Department of Regulatory Agencies. Licensed healing centers began operating in 2025. Adults 21 and older may receive supervised psilocybin and psilocin sessions without a prescription or diagnosis.

Colorado also established a clinical facilitator track for licensed mental and medical health professionals who want to integrate psilocybin services into their existing practice settings. This track involves additional regulatory requirements and allows for more clinically integrated service.

Like Oregon, Colorado’s program is entirely out of pocket. No insurance coverage exists for these services at this time.

New Mexico

New Mexico signed the Medical Psilocybin Act (SB 219) into law on April 7, 2025. Unlike Oregon and Colorado, New Mexico’s program is a medical model: access requires a qualifying condition diagnosed by a licensed healthcare provider. The qualifying conditions specified in the law are major treatment-resistant depression, PTSD, substance use disorders, and end-of-life care. Other conditions may be added by the Department of Health.

The New Mexico program is not yet enrolling patients. The Department of Health is responsible for building the regulatory infrastructure, and the law sets a deadline of December 31, 2027 for full implementation. The Department has stated a goal of enrolling the first patients by the end of 2026. Someone interested in New Mexico should monitor the Department of Health program page rather than expect current access.

Clinical trials

For people outside Oregon and Colorado, or for those who cannot afford out-of-pocket costs, clinical trials are the primary legal pathway. A clinical trial is a federally authorized research study. Participants in psilocybin trials receive the substance under an FDA Investigational New Drug Application, which is the federal authorization that permits Schedule I substances to be used in an approved research context.

Clinical trials for psilocybin are active across the country, studying a range of conditions including treatment-resistant depression, major depressive disorder, PTSD, alcohol use disorder, and end-of-life distress. COMPASS Pathways’ COMP360 psilocybin met its primary endpoint in a Phase 3 trial for treatment-resistant depression in June 2025, with a second Phase 3 trial expected to report in 2026 and a potential NDA submission in late 2026 or early 2027. If approved, that drug would be a synthetic psilocybin prescription product — distinct from the natural psilocybin available through Oregon and Colorado programs.

Clinical trial participation is free to participants, but eligibility is narrow. Most psilocybin trials exclude people with personal or family histories of psychotic or bipolar I disorders, cardiovascular conditions, and people taking SSRIs or other serotonergic medications. Finding a trial requires reviewing ClinicalTrials.gov for open studies, contacting the research site, and completing the enrollment screening process. The time commitment is significant: most trials involve multiple screening visits, medication washout periods, preparation and dosing sessions, and follow-up assessments over weeks or months.

What no pathway provides

No legal pathway in the United States currently permits someone to simply obtain psilocybin and use it at home for therapeutic purposes. Colorado’s law permits personal possession and cultivation for adults 21 and older, but this is a personal-use decriminalization, not a medical authorization or regulated access channel. Possessing psilocybin at home without a clinical context does not create a medical or therapeutic framework around the experience.

No licensed US program currently provides MDMA-assisted therapy. MDMA remains Schedule I with no approved state program. The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024.

No licensed US program currently provides ibogaine, DMT, or mescaline in a regulated supervised therapeutic setting.

Ketamine occupies a different legal category entirely. Ketamine is a Schedule III controlled substance and can be prescribed off-label by physicians. Esketamine (Spravato) is FDA-approved for treatment-resistant depression and administered in certified clinic settings. For many people, ketamine clinics are the most accessible legal option for treatment-resistant conditions right now, though ketamine and psilocybin produce different effects through different mechanisms.

The federal law context

Psilocybin remains Schedule I under the Controlled Substances Act. Oregon and Colorado programs operate under state law only. Participants in those programs are protected from state prosecution within the regulated framework, but no state program provides federal legal protection. A federal prosecution of a participant in an Oregon or Colorado service center session would be legally permissible under the CSA, though no such prosecution has occurred in the context of the licensed programs.

Someone traveling from another state to use Oregon or Colorado services faces no additional state-law risk for traveling — the services themselves are regulated — but carries their home state’s laws with them to the extent any substance is taken out of the state.

Common misconceptions

“My doctor can refer me to psilocybin therapy.” No referral system exists. Oregon and Colorado programs do not require or use physician referrals. No US physician can prescribe psilocybin at this time.

“If research shows it works, it must be available.” Positive research findings do not change the legal status of a substance. Psilocybin has produced promising results in clinical studies for depression, PTSD, and end-of-life distress. None of that research, including studies with strong outcomes, has made psilocybin available through a standard medical prescription channel in the United States. The FDA process for approving a new drug is separate from the legal status of the underlying substance.

“Decriminalization in my city means I can access psilocybin therapeutically.” Decriminalization reduces the risk of criminal prosecution for personal possession. It does not create a legal market, a regulated provider network, or a therapeutic framework. A decriminalized city has no licensed service centers or facilitators operating under a state program.

“The New Mexico program is available now.” It is not. The law has passed, but the regulatory program is still under construction. No patients are being enrolled as of early 2026.

When public information may be enough

If your question is what legal options currently exist, this article covers that. For program-specific information, Oregon psilocybin services explained for clients and Colorado natural medicine explained for participants go deeper into each program’s structure, process, and what to expect. For the difference between state access programs and clinical trials, Clinical trials vs. legal access programs: what’s the difference? covers that in detail. For how FDA approval interacts with legal access, What FDA approval does and does not mean for psychedelic treatments addresses that directly. To understand what access means without a prescription, Do I need a prescription for psychedelic treatment or services? explains the structure of each pathway.

When you should speak with a lawyer

You should speak with a lawyer if:

You are a healthcare provider who has a patient asking about psilocybin and you want to understand what you can and cannot say or do in your professional capacity
You are considering traveling to another state or country for psilocybin access and have concerns about professional consequences, employment, or licensing
You have a specific situation involving prior drug convictions, professional licenses, security clearances, or federal employment that you want to think through before participating in any program
You are a family member or caregiver of a patient with end-of-life distress who wants to understand what is legally available and whether any provider in your area operates within a regulated framework

For help finding a lawyer in this area, What to gather before booking a consult with a psychedelic lawyer explains what information to bring to a first consultation.

For help finding a licensed facilitator or service center, How do I find a licensed psychedelic facilitator or service center? covers how to verify a provider is operating within a regulated program.

You might also want to read

This article is public legal education, not legal advice. If your situation is specific, speak with a lawyer who practices in this area.